Long-term survivors after allogeneic hematopoietic stem cell transplantation (allo-HSCT) are at high risk for treatment-related adverse events, that may worsen physical capacity and may induce fatigue and disability. The aims of this prospective study were to evaluate exercise capacity in allotransplant survivors and its relationship with fatigue and disability. Patient-reported outcomes and exercise capacity were evaluated in 71 non-relapse patients 1 year after allo-HSCT, using validated questionnaires, cardiopulmonary exercise testing (CPET) with measure of peak oxygen uptake (peakVO 2 ) and deconditioning, pulmonary function testing, echocardiography and 6-min walk test. A high proportion (75.4%) of allo-HSCT survivors showed abnormal cardiopulmonary exercise testing parameters as compared to predicted normal values, including 49.3% patients who exhibited moderate to severe impairment in exercise capacity and 37.7% patients with physical deconditioning. PeakVO 2 values were not accurately predicted by 6-min walk distances (r = 0.53). Disability and fatigue were strongly associated with decreased peakVO 2 values (p = 0.002 and p = 0.008, respectively). Exercise capacity was reduced in most allo-HSCT longterm survivors. Because reduced exercise capacity was associated with fatigue, disability and a decrease in quality of life, cardiopulmonary exercise testing should be performed in every patient who reports fatigue and disability.
Introduction
Continuous progress in conditioning regimen and transplantation process in allogeneic hematopoietic stem cell transplantation (allo-HSCT) translates into an increasing population of long-term survivors who are at high risk of treatment-related late adverse events [1] . These events impact directly cardiopulmonary and musculoskeletal functions and may worsen physical capacity and reduce quality of life [2] [3] [4] . The need for cardiorespiratory fitness evaluation is becoming increasingly important, since physical activity has been highlighted as a modifiable nonpharmacological factor that may improve the length and quality of life among cancer survivors, [5] [6] [7] [8] including haematological patients [9] [10] [11] [12] [13] [14] [15] .
Cardiopulmonary exercise testing (CPET) is the most accurate tool to evaluate cardiorespiratory fitness, to identify the main factors limiting exercise tolerance, and to set up an individual rehabilitation program with exercise targets if needed. Currently, CPET is not performed in the followup of allotransplants survivors in contrast to lung function tests and echocardiography, two tests performed at rest. A few studies analysed CPET findings on small numbers of allo-HSCT survivors (inferior to 20 patients) in the limited context of exercise intervention benefits [11, 12] . In auto-HSCT survivors, two studies evaluated cardiorespiratory fitness by CPET, including Stenehjem et al. who reported that 22% of patients from a 200-patient cohort had an impaired exercise capacity at 10 years post transplantation [16, 17] . Alternatively, physical function in chronic diseases such as chronic obstructive pulmonary disease (COPD) or heart failure is often assessed by submaximum exercisetesting such as the 6-min walk test (6MWT), one of the most common field-tests used in the follow-up of such patients. However, the 6MWT only gives an extrapolation of cardiorespiratory fitness from submaximum exercise [18] and no data are available in the allotransplant setting.
In this prospective study we performed a full assessment of exercise capacity and quality of life (QOL) at 1 year in non-relapse allotransplanted patients. The aims of the present study were to evaluate the proportion of allo-HSCT survivors with impaired exercise capacity and the relationships between fatigue, disability and exercise capacity and to determine whether a simpler test such as 6MWT can substitute CPET in the assessment of exercise capacity.
Materials and methods

Study design
This was a single arm prospective and monocentric cohort study conducted at CHU of Nantes. As such, all consecutive adults (≥18 years old) receiving an allo-HSCT and alive 1-year after transplant without relapse were included, for a 2-year period of inclusion. All tests were performed during a 1-day standard exploration at 1 year post transplantation. Furthermore, retrospective data were collected on the total of patients who underwent allo-HSCT 1 year before and after the beginning of inclusion. In those patients, death, relapse, hospitalisation at the time of 1-year evaluation, and 1-year post-transplant check-up in other hospital were also collected between allo-HSCT and 1-year post allo-HSCT. The study was approved by the Ethics Committee of Nantes, France (REF: 2013-12-08) and all patients provided written informed consent.
Quality of life
Various self-administered questionnaires were used: (i) the Medical Outcomes Study Short Form 36 (SF-36) [19] , a 36 items generic multidimensional quality of life measure including Physical Functioning (PF), Role Physical (RP), Physical Component Summary (PCS) and Mental Component Summary (MCS) scales allowing to compare scores with those observed for the general population [20] ; (ii) the Hospital Anxiety and Depression scale (HAD), a score ≥11 defining patients suffering from anxiety or depression [21] and (iii) the St. George's Respiratory Questionnaire (SGRQ) [22] .
Disability was self-reported by patients with a simple binary question: "In the daily life, do you experience disability?". We observed in the first enrolled patients that some of them reported "fatigue" as an important and persistent symptom in their daily life. The SF-36 provided self-report measurement of physical and mental health, but was not an effective tool for evaluating the "fatigue" symptom because of the lack of specific questions. Fatigue was then evaluated by a simple numeric rating scale (NRS) from 0 to 10, and defined as NRS ≥ 5 [23, 24] .
Physical activity and exercise capacity measurements
To assess physical activity before, during and after (including at the time of the present study) transplant, bicycle ergometer practice in the sterile unit and reported one-time per week exercises were considered. Patients were required to retrospectively provide approximately the average duration in minutes (min) of physical activities for each period of time. Patients were then classified according to whether they had performed exercise less or more than 150 min per week, according to international exercise guidelines [25] .
The CPET was performed using the Ergocard ® (Hyp'air, Medisoft, Sorinnes, Belgium) and the electronically braked cycle ergometer Ergoselect (ergoline GmbH, Bitz, Germany), with a 12-lead electrocardiogram (ECG) and blood pressure monitoring. The protocol included a 3-min rest period, a 3-min warm-up of unloaded pedalling followed by a 5-20 W/min incremental phase, up to exhaustion [26] . Dyspnea and leg fatigue intensity were assessed with the Borg scale every 2-min up to exhaustion [27] . This includes the maximal or peak oxygen uptake (peakVO 2 ), the ventilatory threshold (VT), the VO 2 at VT (VO 2 -VT), and the subjective perception of exertion. Peak aerobic exercise capacity (peakVO 2 ) was expressed in mL/min/kg and percentage of the predicted normal value (PNV) [28] . Normal, mild, moderate or severe impaired exercise capacity were defined, respectively, as a peakVO 2 percentage > 80%, between 71 and 79%, between 51 and 70% or ≤ 50% of the predicted normal value [28] . A combined approach was used to calculate VT, based on the identification of the inflection point during the incremental exercise (i) of the respiratory equivalent for oxygen (VE/VO 2 ) curve with time, (ii) of the minute-ventilation (VE) curve with time, or (iii) the VO 2 -VCO 2 relationship. The 9-panel graphical representation of Wasserman et al. was also used to optimize the VT position [29] . Deconditioning was defined by VT < 40% predicted VO 2 max. The 6MWT was performed according to the ERS/ATS guidelines [30, 31] . Patients were required to walk as fast as possible, without running, and to cover the longest possible distance during 6 min under the supervision of a certified physiotherapist (BlueNight Oximeter®). The 6MWD was expressed in meters and as a percentage of the predicted normal value for age and gender, according to Enright equation [32] .
Pulmonary and cardiac function at rest
All pulmonary function tests were performed in the Pulmonary Function Lab according to recommendations [33] . Transthoracic echocardiography was performed according to a standardized protocol (see Supplementary Material).
Statistical analysis
To evaluate the association between exercise capacity and 6MWD, a linear regression model was used to correlate and predict peakVO 2 from the 6MWD. Residuals of the linear regression were analysed to evaluate departure between observed peakVO 2 and predicted peakVO 2 from 6MWD data. Differences between observed and predicted peakVO 2 were represented using histograms. All statistical analyses were performed using R statistical software [34] .
Continuous data were presented using mean ± standard deviation and with percentile p50 (p25-p75) when appropriate, categorical data were presented using raw counts and percentages. Association between categorical variables was expressed using odds ratios (ORs), with 95% confidence interval. The statistical significance of comparison between continuous variables (exercise capacity, quality of life score) was assessed using Mann Whitney (2 groups) or Kruskall Wallis tests (more than 2 groups).
The statistical significance of association between variables was assessed using chi-square test, t-test (after exclusion of non-normal distribution) and Fisher's exact test when appropriate. Results were graphically illustrated using boxplots and spine plots. p-Values were twosided and reported without correction for multiple hypothesis testing. In a second step, major risk factors for post allo-HCST complications (including age, gender, conditioning intensity, GVHD presence) were introduced into a multivariate logistic regression analysis for prediction of peakVO 2 results (odds ratio with 95% CI). The threshold for statistical significance was defined as p < 0.05.
Results
Patients
The study started in May 2012. Although a total of 153 patients underwent an allo-HSCT during the two following years, only 71 cases (46.4%) were enrolled in the present study. The reasons for exclusion at 1 year post-transplant were as follows: death (n = 55, 36%), relapse (n = 8, 5%), hospitalisation at the time of 1-year evaluation (n = 6, 4%) and 1-year post-transplant check-up in other hospital (n = 13, 8%) (Supplementary Figure S1 ). Demographic and transplant characteristics of the 71 allo-HSCT 1-year survivors are summarized in Table 1 . Similar characteristics were shared by the 13 patients who underwent 1-year evaluation outside of our department (data not shown). Mean interval between allo-HSCT and 1-year post-transplant evaluation was 14 months (range, 11-18 months). At this time, 14 (20%) patients were still under corticosteroid medication for GVHD treatment. Lung function tests were normal in most patients (83%) and in the 69 patients who underwent echocardiography, results were normal with a mean LVEF of 64 ± 5.7% (Table 2) . One patient out of 4 with obstructive lung function and 2/8 patients with restrictive lung defect were on steroid.
Self-reported symptoms and quality of life
Among the 71 patients, 26 (36.6%) reported disability at 1 year after allo-HSCT (Table 2) . Importantly, 18/53 (34%) patients reported fatigue at 1 year post allo-HSCT. Interestingly, most patients with fatigue presented also disability (n = 11/18, 61%).
In QOL evaluation using self-administered questionnaires, scores related to physical health were the most impaired ones as compared to scores in the general population. Role limitations due to physical health were experienced by 62.3% of the patients (Table 2) . Furthermore, PCS score (that represents the mean average of all of the physically relevant questions) was significantly lower than the general population in 69.2% of the patients (44.73 ± 8.32 vs. 50.11 ± 5.79, p < 0.001). Finally, a lower general health perception was reported by 65.7% of the patients, showing a frequent alteration in QOL ( Table 2 ). The MCS score was not significantly different NRS numeric rating scale, FEV1 forced expiratory volume in one second, FVC forced vital capacity, TLC total lung capacity, DLCO lung carbon monoxide diffusing capacity, PeakVO 2 peak oxygen uptake, SF-36 36-item short form health survey, Pred. predicted normal value from the general population (48.50 ± 10.39 vs. 48.14 ± 6.66, p = 0.78), suggesting that impaired QOL was more related to physical impairment than mental health deficit. These results were consistent with the low rate of patients reporting anxiety or depression on the HAD scale ( Table 2 , score > 11, n = 13/71 (18.3%)). No significant relationships were observed between peakVO 2 and SGRQ (data not shown), suggesting that this questionnaire is not relevant to detect patients with exercise capacity impairment.
Exercise capacity measurements
Despite normal lung function tests and echocardiography findings in most patients, only 17 (24.6%) had a normal exercise capacity on CPET and 52 (75.4%) and impaired exercise capacity (Table 2) , while nearly half of the studied population (n = 34, 49.3%) showed moderate to severe impairment in exercise capacity, as defined by a peakVO 2 inferior to 70%pred. Importantly, deconditioning, defined by a ventilatory threshold <40% predicted VO 2 max, affected 26 patients (37.7% of the population).
Neither peakVO 2 nor deconditioning condition was associated with DLCO, conditioning regimen, chronic GVHD, or corticosteroid treatment (data not shown). An exploratory multivariate analysis including major risk factors for post allo-HSCT complications (age, gender, conditioning intensity, GVHD) did not predict peakVO 2 results (p = 0.4).
In parallel, mean 6MWD was 470.4 ± 85 m (83 ± 16% pred.). Interestingly, in 26 (37.7%) patients, the 6MWD was inferior to 80% pred. (Table 2 ), a similar proportion to that of patients with impaired cardiorespiratory exercise capacity. However, only 19 patients presented both impaired cardiorespiratory exercise capacity and impaired 6MWD.
Relationship between peakVO 2 and 6MWD
There was a significant correlation between 6MWD and peakVO 2 (Pearson's coefficient correlation = 0.53, p = 3.95 × 10 −6 ), the regression slope indicating that, on average, a 100 m increase of the 6MWD performance was associated with a 4.0 ml/kg/min (95%CI: 2.4 ml/kg/min; 5.5 ml/kg/min) peakVO 2 increase (Fig. 1a) . However, peakVO 2 values were not accurately predicted when based on the sole 6MWD (Fig. 1b) Figure S2) . This result was consistent with results when patients were classified according to the degree of impairment of exercise capacity. Patients with disability had moderate to severe alteration of exercise capacity in 75%, vs. a proportion of 35.6% patients with moderate to severe alteration of exercise capacity in patients who did not report disability (OR = 5.29, p = 0.002, Fig. 2a) . Patients with fatigue presented more frequently with moderate to severe alteration of exercise capacity: 66.7%, vs. 27.3% patients without fatigue (OR = 5.14, p = 0.009, Fig. 2b ). Fatigue but not disability was also significantly associated with deconditioning (patients with fatigue and deconditioning: 55.5% vs. without deconditioning: 21.1% (OR = 4.49, p = 0.028, Fig. 2c, d ). These data suggest that patients with disability or fatigue are at risk of moderate to severe exercise capacity impairment and deconditioning. Finally, patients who reported fatigue or disability did not exhibit any greater alteration of 6MWD as compared to patients Figure S3) . Patients with severe alteration of exercise capacity (according to peakVO 2 value) showed significant impaired physical well-being when considering PF and PCS scores (p < 0.05, Fig. 3a, b) . No significant relationships were observed between peakVO 2 and MCS or HAD scores (data not shown).
Relationship between physical activity and exercise capacity impairment Physical activities were reported by 44, 39 and 43 patients before, during and after transplant, respectively. This includes 9/69 cases with ≥150 min/week of moderate to vigorous intensity exercise. During hospitalisation, the median duration of physical activity on bicycle ergometer was 17.9 ± 14.9 min/day for a median of 15.4 ± 13.4 days. Physical activity before transplant was not associated with a better exercise capacity at 1 year post allo-HSCT (p = 0.2, Fig. 4a ). Conversely, patients with physical activities during (Fig. 4b) or after hospitalisation (including at 1-year evaluation) were documented with significantly better exercise capacity at 1 year, as evaluated by peakVO 2 (p = 0.02, and p = 0.008, respectively). Statistical significance was reached irrespective of the duration of exercise activity (< or ≥150 min/week) during hospitalisation, but only in case of fulfillment of the recommendations about physical exercise (moderate or vigorous intensity, ≥150 min/week) after hospitalisation (data not shown). Exercise capacity should be evaluated, at least in patients who report fatigue and/or disability Although most long-term survivors after allo-HSCT recover adequately from treatment, a substantial proportion continues to experience late effects that reduce health-related quality of life. One of the most prevalent and disturbing long-term symptoms is fatigue, evaluated from 28% at 3 years post allo-HSCT [35] to 35% in another study (mean = 9.3 years) [36] , a proportion close to that in our study. To avoid fatigue, cancer patients are often advised to rest and down-regulate their daily activities. However, these recommendations can cause paradoxical results. Since inactivity induces muscular wasting, prolonged rest can result in further loss of endurance. Our study shows disability and fatigue were both strongly associated to impaired exercise capacity, while recent studies suggest that exercise reduces fatigue and improves the performance status of cancer patients [37] , including patients with allo-HSCT [11, 35] . Altogether these data show a strong and inverted link between fatigue and exercise capacity and suggest that fatigue should be systematically assessed and taken into account in long-term survivor follow-up and CPET should be performed in all long-term survivors post allo-HSCT, to detect low exercise capacity and to set up rehabilitation programs.
CPET is a better exercise capacity assessment tool than 6MWT
Our study reported a high proportion of patients with abnormal CPET (75%) and deconditioning (40%) at 1 year post allo-HSCT while 6MWD misevaluated exercise capacity in more than 50% patients. CPET provides a global noninvasive assessment of the integrative exercise responses which are not adequately reflected through the measurement of individual organ system function [26] . Importantly, peakVO 2 is inversely associated with death from any cause in patients and healthy individuals [38] , including patients with cardiovascular disease [39] and cancer patients in a large meta-analysis [40] , and HSCT patients in a pilot study [41] . Nevertheless, because CPET needs trained personnel, specialized equipment, and medical supervision, it is relatively expensive. As shown in our study and in others [26] , resting pulmonary and cardiac function testing cannot reliably predict exercise performance and functional capacity. 6MWT will not likely replace CPET [26] as studies in respiratory disease suggest that peakVO 2 measurement and 6MWD are not commutable [30] , a data consistent with the poor correlation between 6MWD and peakVO 2 in our patients.
Long-term QOL is impaired mainly due to physical health and physical exercise should be encouraged Similar to results reported by other authors [42, 43] , the level of psychological distress was low in our population. Importantly, impairment of physical well-being on quality of life questionnaires was associated with the most altered exercise capacity, and the degree of physical health impairment (quantified by a PCS score of 44.73) was similar to that in Bevans et al.'s study [43] .
Our study does not address whether improvement in cardiorespiratory fitness via exercise training interventions is an effective strategy to reduce death risk in survivors post allo-HSCT. However, there is considerable evidence that aerobic training interventions following standard exercise prescription according to guidelines have beneficial effects on health-related quality of life domains in cancer survivors [44] including survivors post-HSCT [9] [10] [11] [12] [13] [14] , and recommendations about exercise training have been established for patients with cancer either during treatment or following treatment completion [45, 46] . In four studies where exercise program was performed during hospitalisation for HSCT among 18-100 patients, patients experienced improvement in fatigue, aerobic capacity, muscle strength and quality of life [9, [47] [48] [49] . Results from three other studies implementing exercise intervention 6 months to 3 years after HSCT showed similar benefits [11, 12, 50] .
In summary, long-term survivors after allo-HSCT are considered as a distinct, high-risk population that must be monitored for long-term transplant complications, including altered exercise capacity and deconditioning. Our study supports the recommendation of questioning about fatigue and disability into regular follow-up protocols for allo-HSCT survivors and of CPET measurement in every patient who reports fatigue or disability.
